Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: A systematic review and meta-analysis

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Butalia, Sonia ^a   Leung, Alexander A ^a   Ghali, William A ^a   Rabi, Doreen M ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CARDIOVASCULAR AGENT;

BIOSIS; CLINICAL ASSESSMENT; COCHRANE LIBRARY; CONFIDENCE INTERVAL; DIABETES MELLITUS; DISEASE REGISTRY; DRUG FATALITY; ELECTRONIC MEDICAL RECORD; HEART INFARCTION; HUMAN; INDIVIDUALIZATION; LIMB ISCHEMIA; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PUBLICATION; REVIEW; RISK; STROKE; SYSTEMATIC REVIEW; BLEEDING; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE; FEMALE; GASTROINTESTINAL DISEASE; INCIDENCE; MALE; MORTALITY; PATIENT SELECTION; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; EVIDENCE-BASED MEDICINE; FEMALE; GASTROINTESTINAL DISEASES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; PATIENT SELECTION; PRIMARY PREVENTION; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953246984     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-25     Document Type: Review

References (40)

1. Gerstein HC. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Med Res Rev 2002, 18(SUPPL 3):S82-S85.
2. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342(13):905-912. 10.1056/NEJM200003303421301, 10738048.
3. Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009, 26(2):142-148. 10.1111/j.1464-5491.2008.02640.x, 19236616.
4. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999, 281(14):1291-1297. 10.1001/jama.281.14.1291, 10208144.
5. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 2008, 31(8):1686-1696. 10.2337/dc08-9022, 2494659, 18663233.
6. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339(4):229-234. 10.1056/NEJM199807233390404, 9673301.
7. Nicolucci A, De Berardis G, Sacco M, Tognoni G. AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 2007, 28(16):1925-1927. 10.1093/eurheartj/ehm248, 17604291.
8. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009, 339:b4531. 10.1136/bmj.b4531, 2774388, 19897665.
9. Zhang C, Sun A, Zhang P, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 2010, 87(2):211-218. 10.1016/j.diabres.2009.09.029, 19853947.
10. Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010, 11(9):1459-66. 10.1517/14656561003792538, 20429671.
11. Calvin A, Aggarwal N, Murad H, et al. Aspirin for the primary prevention of cardiovascular evets: A systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009, 32:2300-2306. 10.2337/dc09-1297, 2782995, 19741185.
12. Pignone M, Alberts MJ, Colwell JA, et al. A position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 2010, 33(6):1392-1402.
13. Antithrombotic Trialists' (ATT) Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trial. Lancet 2009, 373(9678):1849-1860. 10.1016/S0140-6736(09)60503-1, 2715005, 19482214, Antithrombotic Trialists' (ATT) Collaboration.
14. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998, 351(9118):1755-1762. HOT Study Group, 10.1016/S0140-6736(98)04311-6, 9635947.
15. Zanchetti A. Aspirin and antiplatelet drugs in the prevention of cardiovascular complications of diabetes. Pharmacotherapy of diabetes: new developments: improving life and prognosis for diabetic patients 2007, 211-218. New York (New York): Springer Science and Business Media.
16. ETDRS Investigators Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992, 268(10):1292-1300. ETDRS Investigators, 10.1001/jama.268.10.1292, 1507375, ETDRS Investigators.
17. Higgins JPT, Green S, . (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 2009, updated September 2009. The Cochrane Collaboration, (editors)., http://www.cochrane-handbook.org
18. Moher D, Liberati A, Tetzlaff J, Altman DG, . for the PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. for the PRISMA Group.
19. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17(1):1-12. 10.1016/0197-2456(95)00134-4, 8721797.
20. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted?. Stat Med 2002, 21(11):1559-1573. 10.1002/sim.1187, 12111920.
21. Akobeng AK. Communicating the benefits and harms of treatments. Arch Dis Child 2008, 93(8):710-713. 10.1136/adc.2008.137083, 18456681.
22. Demaerschalk BM. Thrombolytic therapy for acute ischemic stroke: the likelihood of being helped versus harmed. Stroke 2007, 38(8):2215-2216. 10.1161/STROKEAHA.107.494112, 17641237.
23. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634. 2127453, 9310563.
24. Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol 2005, 15(6):235-243. 10.2188/jea.15.235, 16276033.
25. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008, 300(18):2134-2141. 10.1001/jama.2008.623, 18997198.
26. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840. 10.1136/bmj.a1840, 2658865, 18927173.
27. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005, 352(13):1293-1304. 10.1056/NEJMoa050613, 15753114.
28. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A, . for the PPP Collaborative Group Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003, 26(12):3264-3272. 10.2337/diacare.26.12.3264, 14633812, for the PPP Collaborative Group.
29. The Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321(3):129-135. 10.1056/NEJM198907203210301, 2664509, The Steering Committee of the Physicians' Health Study Research Group.
30. Antithrombotic Trialists' (ATT) Collaboration Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324(7329):71-86. 10.1136/bmj.324.7329.71, 64503, 11786451, Antithrombotic Trialists' (ATT) Collaboration.
31. Antiplatelet Trialists' Collaboration Collaborative overview of randomized trials of antiplatelet therapy-I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308(6921):81-106. 2539220, 8298418, Antiplatelet Trialists' Collaboration.
32. Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care 1998, 21(7):1138-1145. 10.2337/diacare.21.7.1138, 9653609.
33. Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care 2000, 23(7):962-968. 10.2337/diacare.23.7.962, 10895847.
34. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2(2):120-126. 10.2337/diacare.2.2.120, 520114.
35. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009, 23(3):375-388. 10.1016/j.beem.2008.12.001, 19520310.
36. Colwell JA. Antiplatelet agents for the prevention of cardiovascular disease in diabetes mellitus. Am J Cardiovasc Drugs 2004, 4(2):87-106. 10.2165/00129784-200404020-00003, 15049721.
37. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)- its relation to metabolic control. Thromb Res 2004, 113(2):101-113. 10.1016/j.thromres.2003.12.016, 15115665.
38. Watala C, Pluta J, Golanski J, et al. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 2005, 83(2):148-158. 10.1007/s00109-004-0600-x, 15723265.
39. De Berardis G, Sacco M, Evangelista V, et al. the ACCEPT-D Study Group Aspirin and simvastatin combination for cardiovascular events prevention trial in diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subject with diabetes mellitus treated with statins. Trials 2007, 8:21-29. 10.1186/1745-6215-8-21, 2014771, 17725825, the ACCEPT-D Study Group.
40. A Study of Cardiovascular Events in Diabetes (ASCEND). , http://www.ctsu.ox.ac.uk/ascend